AUPH Aurinia Pharmaceuticals Inc

6.36
-0.23  -3%
Previous Close 6.59
Open 6.54
Price To book 9.68
Market Cap 339.80M
Shares 53,428,000
Volume 2,655,580
Short Ratio 0.88
Av. Daily Volume 9,366,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 trial initiation announced May 15, 2017.
Voclosporin - AURORA
Lupus

Latest News

  1. Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis
  2. Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics
  3. Aurinia reports 1Q loss
  4. Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
  5. Aurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : May 11, 2017
  6. Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
  7. Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : May 9, 2017
  8. Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
  9. 3 Best Biotech Stocks During Trump's First 100 Days
  10. Aurinia to Present at Bloom Burton & Co. Healthcare Conference
  11. Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals
  12. Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings
  13. This Trading-Range Action Is Not Offering Much
  14. Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock Options
  15. Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome
  16. Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL
  17. Aurinia Pharmaceuticals Plans to Take a Big Step Forward
  18. Here's Why Aurinia Pharmaceuticals Rose as Much as 10.8% This Morning
  19. Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial
  20. Aurinia Plans Phase 3 Study for Lupus Drug